

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.:
L74899DL1993PLC056594

Ref: STEX/Results/Published-2021-22

Date: 16.08.2021

The BSE Ltd
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Company Number: 531146

Sub. : Copy of Publication for Un-audited Financial Results for the quarter ended June 30, 2021

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 ("the Regulations"), please find enclosed herewith the Un-audited Financial Results of the Company for the quarter ended on June 30, 2021 approved by the Board of Directors at their Meeting held on 13.08.2021.


The copy of the results published in the Financial Express and Jansatta dated August 14, 2021 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited


Parul Choudhary
Company Secretary
ACS-44157

Encl: As above.

PANY LIMITED

clave, New Delhi - 110017

in

RESULTS FOR

(Rs. in lakhs)

Year to date figures/ previous year ending 31.03.2021	Corresponding 3 months ended in the previous year 30.06.2020
31.18	2.26
15.94	(2.06)
47.42	22.75
300.00	300.00
14.52	14.52
1.58	0.76
1.58	0.76

the Board of Directors at their

its filed with the Stock Exchange (Regulations), 2015. The full format is available on the Stock Exchange's website. (URL of the filings).

Member of the Board of Directors
Investment Company Limited

Sd/
Sanyam Tuteja
Director
DIN: 08139915

U40106GJ2020PLC113100
and.com; Website: www.iwcl.co.in

RESULTS (Rs. in Lakh)

Period from 06.03.2020 to 03.2021 Audited	Quarter ended 30.06.2020 Unaudited
71,761	6,392
(47,140)	(10,925)
(33,146)	(10,172)
(33,105)	(10,178)
1,52,934	1,099
1,099	1,099
(301.74)	(92.60)
(301.74)	(92.60)

approved by the Board of Directors at its meeting held out Limited Review of the above

its filed with the Stock Exchange (Regulations), 2015. The full format is available on the Stock Exchange's website (www.iwcl.co.in).

(Rs. in Lakh)

Period from 06.03.2020 to 03.2021 Audited	Quarter ended 30.06.2020 Unaudited
761	177
(1,231)	107
(2,434)	(2,845)

On behalf of the Board of Directors

For Inox Wind Energy Limited

Sd/
Vineet Valentine Davis
Whole-time Director



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594 E-mail : cs@medicamen.com, www.medicamen.com

Extracts of Un-Audited Standalone & Consolidated Financial Results for the Quarter ended on 30.06.2020 (In Lakhs)

Sl. No.	Particulars	Standalone				Consolidated			
		Quarter Ended			Year Ended	Quarter Ended			Year Ended
		3 Months Ended 30.06.2021 Un-Audited	Preceding 3 Months ended 31.03.2021 (Audited)	Corresponding 3 Months ended 30.06.2020 (Un-Audited)	31.03.2021 Audited	3 Months Ended 30.06.2021 Un-Audited	Preceding 3 Months ended 31.03.2021 (Audited)	Corresponding 3 Months ended 30.06.2020 (Un-Audited)	31.03.2021 Audited
1	Total income from operations (net)	2760.90	2087.46	2619.93	11090.06	2760.90	2177.60	2786.76	11347.01
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	474.57	464.35	305.27	1675.12	474.57	410.07	323.82	1639.40
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	474.57	464.35	305.27	1675.12	474.57	410.07	323.82	1639.40
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	415.13	414.34	210.49	1248.66	415.13	364.69	224.41	1212.94
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)								
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)								
	Basic:	3.40	3.39	1.72	10.22	3.40	2.99	1.84	9.93
	Diluted:	3.40	3.39	1.72	10.22	3.40	2.99	1.84	9.93

Note:

- The Un-audited financial results for the quarter ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13.08.2021.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share".
- During the quarter under review, beta lactum block was shut down for 5-6 weeks for upgradation.
- The Pharma Oncology formulation plant at Haridwar which has commence its operations in the month of March 2021, major revenue/ income from oncology plant will come after US FDA approval. However oncology plant will start generating income from domestic operations and exports to ROW markets after validations are completed.
- Audit report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited

Sd/
Rahul Bishnoi
Chairman

Place: New Delhi

Date: 13.08.2021

FORTUNE INTERNATIONAL LTD

CIN : L52324DL1981PLC012033

Regd. Office: G-4, Community Centre, Naraina Vihar, New Delhi-110028
E-Mail ID for investors: rekha.srivastava2016@gmail.com, Tel: 011-25774212-214

Extract of Un-audited Standalone and Consolidated Financial Results for the Quarter ended on 30th June, 2021

(Figures in lakhs)

Particulars	Standalone Results				Consolidated Results			
	Quarter ended 30.06.2021 (Unaudited)	Quarter ended 31.03.2021 (Audited)	Quarter ended 30.06.2020 (Unaudited)	Year ended 31.03.2021 (Audited)	Quarter ended 30.06.2021 (Unaudited)	Quarter ended 31.03.2021 (Audited)	Quarter ended 30.06.2020 (Unaudited)	Year ended 31.03.2021 (Audited)
	Total income from operations (net)	43.39	322.78	-	382.18	43.39	322.78	-
Net Profit/(Loss) for the period (before tax, exceptional and/ or extraordinary items)	20.05	298.14	-1.36	340.24	20.05	298.14	-1.36	340.24
Net Profit/(Loss) for the period before tax (after exceptional and/ or extraordinary items)	20.05	298.14	-1.36	340.24	20.05	298.14	-1.36	340.24
Net Profit/(Loss) for the period after tax (after exceptional and/ or extraordinary items)	20.05	298.14	-1.36	340.24	20.05	298.14	-1.36	340.24
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	20.05	298.14	-1.36	340.24	265.32	514.37	183.38	1137.81
Paid up Equity Share Capital	704.00	704.00	704.00	704.00	704.00	704.00	704.00	704.00
Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	-	-	-	-716.81	-	-	-	-1334.48
Earnings Per Share (for continuing and discontinued operations)								
Basic :	0.28	4.23	-0.02	4.83	3.77	7.17	2.60	16.02
Diluted:	0.28	4.23	-0.02	4.83	3.77	7.17	2.60	16.02

तिमूर्ति हित प्रवर्तन
हाउसिंग फाइनेंस
नियमावली, 2002 के
प्रयोग करते हुए
05.2021 जारी कर
की तिथि से 60 दिनों
लाख छियालीस
दिया था।

हणधारक तथा आम
उक्त नियमावली के
शक्तियों का प्रयोग

है कि वे यहां वर्णित
साय को बकाया रु.
यानवे एवं अडतीस
लिमिटेड के चार्ज के

लक्ष समय के संदर्भ
जाती है।

स वनेशिया हार्डवेस,
नोएडा, यूपी-201308

प्राधिकृत अधिकारी
फाइनेंस लिमिटेड

ATED
512-2531762
dsurfactants.com
50

ED ON 30-06-2021
(Rs. in Lacs)

Quarter Ended
2021 30.06.2020
ited) (Unaudited)

5.13 1886.59
4.39 95.46

4.39 95.46

4.02 71.20

4.02 71.20
1.26 711.26

1.60 1.00
1.60 1.00

approved by the Board
itors have carried out

s filed with the Stock
losure Requirements)
are available on stock

Surfactants Limited
Pawan Kumar Garg
& Managing Director
DIN-00250836

पर सुनवाई करते हुए न्यायमूर्ति धनंजय यशवंत चंद्रचूड़ और
न्यायमूर्ति एमआर शाह की एक पीठ ने एनजीटी के आदेश पर

2010 की धारा 25 के तहत कड़ी कार्रवाई क्रमों न की जाए। कर
सुप्रीम कोर्ट ने ग्रेटर मुंबई नगर निगम को न्यायाधिकरण के और

सई
(आईसीए
में आबाद

Sl. No.		Particulars		Standalone				Consolidated			
				Quarter Ended		Year Ended		Quarter Ended		Year Ended	
				3 Months Ended 30.06.2021 Un-Audited	Preceding 3 Months ended 31.03.2021 (Audited)	Corre-sponding 3 Months ended 30.06.2020 (Un-Audited)	31.03.2021 Audited	3 Months Ended 30.06.2021 Un-Audited	Preceding 3 Months ended 31.03.2021 (Audited)	Corre-sponding 3 Months ended 30.06.2020 (Un-Audited)	31.03.2021 Audited
1	Total income from operations (net)	2760.90	2087.46	2619.93	11090.06	2760.90	2177.60	2786.76	11347.01		
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	474.57	464.35	305.27	1675.12	474.57	410.07	323.82	1639.40		
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	474.57	464.35	305.27	1675.12	474.57	410.07	323.82	1639.40		
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	415.13	414.34	210.49	1248.66	415.13	364.69	224.41	1212.94		
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66		
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)										
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)										
	Basic:	3.40	3.39	1.72	10.22	3.40	2.99	1.84	9.93		
	Diluted:	3.40	3.39	1.72	10.22	3.40	2.99	1.84	9.93		


Note:

- The Un-audited financial results for the quarter ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13.08.2021.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 "Earning per Share"
- During the quarter under review, beta lactum block was shut down for 5-6 weeks for upgradation.
- The Pharma Oncology formulation plant at Haridwar which has commence its operations in the month of March 2021, major revenue/ income from oncology plant will come after US FDA approval. However oncology plant will start generating income from domestic operations and exports to ROW markets after validations are completed.
- Audit report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.


For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

Place: New Delhi
Date : 13.08.2021

Place: New De
Date: 13.08.20



जगन लैम्स लिमिटेड
सीआइएन : L31501HR1993PLC033993



SANGAL PAPERS LIMITED
REGD. OFFICE: VILL. BHAINSA
P.O. SANDHAN, MAWANA, UP-25